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The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of
metastasized cancer diseases. It can be produced in nuclear research reactors,
irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for
receptor-targeted radionuclide therapy, where high specific molar activities are required.
In this study, an electromagnetic isotope separation technique was applied after neutron
irradiation to boost the specific activity by separating 169Er from 168Er targets. The
separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent
chemical purification process was developed as well as activity standardization of the
radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling
and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a
169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.
Keywords: Er-169, electromagnetic isotope separation, lanthanide-separation, activity standardization, in vitro
studies, laser resonance ionization
INTRODUCTION
Radiolanthanides are of particular interest in the field of nuclear medicine, offering attractive
decay properties for both diagnosis and therapy (1–6). One of the most intriguing features of the
radiolanthanides, other than having promising physical decay properties, is that they have similar
chemical characteristics, and analogous coordination chemistry, which allows one to perform
comparative pre-clinical studies. A significant disadvantage of lanthanides, however, is that they
are difficult to chemically separate and isolate.
Currently, the β−-emitting 177Lu is used on a routine basis in clinics for targeted radionuclide
therapy. The Center of Radiopharmaceutical Sciences (CRS) at Paul Scherrer Institute (PSI) has
recently introduced 161Tb as a potentially better alternative to 177Lu due to its co-emission of
conversion and Auger electrons (Table 1). There is good reason to assume that conversion and
Auger electrons emitted by 161Tb, in addition to β−-particles, have an additive therapeutic effect
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TABLE 1 | Comparison of decay properties and Auger electron/Conversion




Energy (keV) Intensity (%)
161Tb 6.96 d 154 CE K 3.4 17.5
Auger L 5.2 87.9
CE L 16.6 41.0
CE K 20.8 5.7
CE M 23.6 9.2
169Er 9.39 d 100 CE M 6.1 36.0
CE N 7.9 8.2
165Er 10.36 h _ Auger L 5.3 65.6
Auger K 38.4 4.8
Only the high intensities are shown (data are taken from1 ).
(7). However, further studies are needed to investigate the
contribution of conversion and Auger electrons in more detail.
In this regard, the use of radionuclides with either β−- or Auger-
electron emission would be ideal to investigate. The matched
pair of 169Er (pure β−-particle emitter) with the pure Auger-
electron emitter 165Er can, thus, represent an ideal model system
to evaluate the additive therapeutic effect of Auger electrons on
targeted β− therapy.
169Er (t1/2 = 9.39 d, Eβ
−
av = 100 keV
1) and 165Er (t1/2 =
10.36 h) have promising decay properties toward radionuclide
therapy of metastasized cancer diseases (Table 1). Dosimetry
calculations showed that 169Er displayed higher tumor-to-
normal-tissue absorbed dose ratio (TND) values than the
currently clinically-used radiolanthanide 177Lu (8) for tumor
sizes from 102 to 10−9 g (3), which is ascribed to its soft β−-
radiation and the negligible photon dose (only 0.017 eV per
decay1). Its low-energy β−-particles have an average soft tissue
range of 0.3mm (9). Moreover, the relatively long half-life of
169Er is considered as an additional advantage to avoid activity
loss during transport and storage. On the other hand, 165Er is
an attractive radiolanthanide for pure Auger-electron therapy. It
decays by electron capture, followed by the emission of Auger
electrons without accompanying γ-radiation, but emission of X-
rays with an average energy of 48.8 keV. Systematic pre-clinical
studies, by combining 169Er and 165Er with varying activity
ratios, would help in understanding the additive therapeutic
effect of Auger electrons, which requires the availability of these
radionuclides in a suitable quality for pre-clinical studies.
Erbium-169 is currently produced by neutron irradiation of
highly-enriched (98.2%) 168Er2O3 targets in nuclear reactors. In
this way, it can only be produced with low specific activity in
the carrier-added form due to the relatively low neutron capture
cross-section of 168Er (σ: 2.3 barn) (10). To date, 169Er has
only been used as a colloid in citrate form for the treatment
of chronic rheumatoid arthritis, inflamed synovium by means
of irradiation and to improve joint function (9, 11–18). For
this purpose, low-specific activities are acceptable. However, for
1https://www.nndc.bnl.gov/nudat2/ (accessed March 3, 2021).
tumor-targeted radionuclide therapy, 169Er is required as a high-
specific activity product.
A combination of mass and chemical separation, to obtain
high-purity radionuclides for nuclear medicine applications,
represents an innovative approach to achieve this goal (19–
21). As proof-of-principle experiments, the ISOLDE (Isotope
Separation On-Line) facility at CERN was used for the mass
separation of medically-researched terbium radionuclides (22–
25). Neutron-deficient diagnostic and therapeutic terbium
radionuclides [152Tb (19, 20, 26–29), 155Tb (27, 30), and 149Tb
(21, 27, 31, 32)], were separated at ISOLDE and, after chemical
separation at PSI, utilized for pre-clinical in vitro and in vivo
studies. Similar mass separation techniques have recently been
used at the CERN-MEDICIS facility with off-linemass separation
capabilities (33–40). An 169Er mass separation proof of concept
(up to 17 MBq), obtained from reactor-irradiated enriched
168Er targets, was previously performed using an electromagnetic
isotope separation (EMIS) method (37).
In the present work, an offline mass separation technique was
used in combination with a resonance laser ion source (34, 39,
41, 42), which ensured the increase of efficiency and selectivity
for 169Er. The activities produced were sufficient to perform
one preliminary in vitro assay. Previously, ionization efficiency
values in the order of 20–50% (on mass separators equipped
with laser ion sources) were reported for holmium, dysprosium
and lutetium (38, 43, 44). Similar results were also obtained
at the CERN-MEDICIS facility for 167Tm (45), indicating
room for separation efficiency improvements for 169Er. In
addition to higher separation efficiencies, longer irradiation times
and minimum activity loss during radiochemical separation
and transport will allow one to produce 169Er in much
higher activities for comprehensive pre-clinical studies and, to
evaluate the potential of this novel radionuclide for future
clinical applications.
This systematic study consisted of several steps, namely,
irradiation, mass separation, radiochemistry, quality control, and
radiolabeling, to obtain a standard procedure for the production
of 169Er in view of its use for receptor-targeted radionuclide
therapy (Figure 1). After the mass separation process, the
subsequent chemical separation method was developed to obtain
169Er in a solution of sufficient quality to enable radiolabeling of
tumor-targeting agents. The activity standardization of 169Er was
completed using the triple-to-double-coincidence ratio (TDCR)
technique to perform precise activity measurements (46). A
preliminary in vitro experiment was carried out to assess
tumor cell viability upon exposure to 169Er-labeled PSMA-617
using cancer cells expressing the prostate-specific membrane
antigen (PSMA).
MATERIALS AND METHODS
Production of Carrier-Added 169Er
Enriched 168Er2O3 (98.0%, ISOFLEX, USA and 98.2% Trace
Sciences Int., Canada) was used as target material for the
production of 169Er via the 168Er(n, γ)169Er nuclear reaction. The
168Er2O3 samples (7.9–14.2mg) were sealed in quartz ampoules
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FIGURE 1 | Stepwise production of 169Er for receptor-targeted radionuclide therapy (chemical set up image was taken from https://thenounproject.com/ under the
license number: ch_0GVAv9Ol-QUEvnWfJrWcOvos9).
TABLE 2 | The list of the used and characterized samples.
Samples Characterization
Enriched 168Er2O3 (Isoflex) ICP-MS
Enriched 168Er2O3 (Trace Sciences) ICP-MS
Carrier-added 169Er (b.e. Imaging) Activity standardization (TDCR)
Seven samples after mass separation γ-ray spectrometry
Seven samples after mass and
chemical separation
Quality control analyses (section Quality
Control)
and irradiated in the V4 irradiation position of the high-
flux reactor at Institute Laue–Langevin (ILL), Grenoble, France
(thermal neutron flux ≈ 1.1 1015 n.cm2.s−1, irradiation time: 7
days, 169Er theoretical yield: 25-48 GBq). After irradiations, the
ampoules were transported to the CERN-MEDICIS facility for
the offline mass separation of A= 169.
Carrier-added 169Er, supplied as a colloidal suspension of
169Er-citrate from Curium (Swiss distributor: b.e. imaging
GmbH), was used as a representative sample for post-irradiation
and after chemical separation for activity standardization. The
list of all the characterized samples, using different techniques,
is given in Table 2.
Mass Separation
MEDICIS’ Laser Ion Source for Separator Assembly (MELISSA)
(39) was utilized for the offline mass separation of 169Er.
169Er-containing ampoules were opened and transferred into an
ISOLDE standard tantalum target container (25). The container
was connected to a rhenium ion source via a transfer line.
The extraction electrode was positioned after an acceleration
gap of 60mm from the ion source’s exit. Respective currents
of 250A and 300A were applied to heat the target, as well
as the line, and to allow for preliminary optimization steps
on stable 168Er. 169Er was extracted from targets that were
heated up to 2,200◦C (corresponding to a current of 730A). The
current laser setup consists of two Z-cavity Ti:sapphire lasers,
designed by Mainz University (47), each pumped by a dedicated
commercial InnoLas Nanio 532-18-Y laser system. The two-
step laser resonance ionization scheme for erbium was used;
the optimized wavelengths during the collections were 24943.95
cm−1 for TiSa n◦2 and 24337.32 cm−1 for TiSa n◦1, as reported
in (37, 44, 48). The ions were electrostatically accelerated to 60
keV and mass-separated with a magnetic sector field.
The mass-separated A = 169 beam, containing 169Er, was
implanted into a solid catcher (zinc-coated gold foil). Gold
foils (thickness: 0.1mm, purity: 99.95%, Goodfellow Cambridge
Ltd. Huntingdon, UK) were coated with 500 nm Zn (99.995%
Zn granulate from Neyco, France) layer using physical vapor
deposition (PVD) technique. In total, seven mass-separated
samples were shipped to PSI for chemical separation, quality
control, and an in vitro proof-of-concept experiment.
Radiochemical Separation
The radiochemical separation method was developed for
the separation of macro amounts of Zn and as well as
isobaric 169Yb and 169Tm from the desired 169Er. The
gold foil obtained from CERN (Supplementary Figure 1) was
introduced into a reaction vial and the 169Er-implanted Zn
layer dissolved in 7mL 6M HNO3. The resulting solution
was directly loaded onto a column containing N,N,N′,N′-tetra-
n-octyldiglycolamide, non-branched resin (DGA, particle size
50–100µm, TrisKem International, France; volume 0.08mL),
which is based on tetraoctlyldigycolamide as sorbent. The
column was rinsed several times with 6.0M HNO3 and
the Zn concentration in each fraction determined using an
Agilent 5110 Inductively Coupled Plasma Optical Emission
Spectrometry (ICP-OES).
After removal of the macro amounts of Zn; Er, Yb, and
Tm were eluted using 0.05M HCl and loaded onto a column
containing Sykam macroporous cation exchange resin (Sykam
Chromatographie Vertriebs GmbH, Germany; particle size 12–
22µm, NH+4 form; column volume: 2.5mL). Separation of
169Yb
and 169Er was performed with 0.06–0.08M α-hydroxyisobutyric
acid (α-HIBA, Sigma-Aldrich GmbH, Germany) using the Sykam
cation exchange resin separation system. Subsequently, LN3
resin (Triskem International, France; column volume: 0.04mL)
was used to remove the complexing agent (α-HIBA), be an
additional means of Zn removal and to obtain the final product
in chloride form. The use of 2mL 0.02M HCl removed the
Zn from the system, prior to the elution of 169Er (1mL 2.0
M HCl).
As an extra, and final, separation step, 169Er 1mL 2M
HCl solution was passed through a TK200 resin [Triskem
International, France; based on TriOctylPhosphine Oxide
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FIGURE 2 | Scheme of the samples used for the activity standardization and
calibration of the LSC (liquid scintillation counting).
(TOPO), column volume: 0.06mL], for the complete removal of
Zn from the final product. The eluant was, then, heated until
dryness and redissolved in 250 µL 0.05M HCl solution, which
was used for the radiolabeling of PSMA-617.
Quality Control
Activity Standardization
Gamma-ray spectra of the gold foils were taken before and
after leaching of the Zn layer, using a high-purity germanium
(HPGe) detector (Canberra, France), in combination with the
Inter-Winner software package (version 7.1, Itech Instruments,
France) (Supplementary Figure 2).
Purified 169Er in 0.1M HCl (stock solution) was divided
into two parts, named Er1 and Er2, respectively (Figure 2).
They were accurately weighed using a Mettler-Toledo XS225DU
balance. Sample Er1 was sent to the Institute of Radiation Physics
(IRA, Lausanne) for activity standardization using the TDCR
technique. The activity concentration of the Er1 solution was
used to prepare 169Er quench series to calibrate LSC using Er2
solution (Supplementary Figure 3A). The counting efficiency
for typical samples was∼97%.
The 169Er activity measurements of the mass-separated
samples were performed after chemical separation using
liquid scintillation counting (LSC; LSC Packard Tri-Carb 2250
CA) (Supplementary Figure 3B). Further details about activity
standardization measurements of 169Er are described in the
Supplementary Material.
Radionuclidic Purity
After chemical separation, the radionuclidic purity of the samples
was determined using a HPGe detector, as described in section
Activity Standardization.
Isotopic Ratio Measurement
Enriched 168Er2O3 (98.0%, ISOFLEX, USA, and 98.2% Trace
Sciences Int. Canada) and four mass-separated 169Er samples
(S1-S4) were analyzed using a Thermo Fisher Scientific Sector
Field Inductively Coupled Plasma Mass Spectrometer (SF-ICP-
MS) Element II R©. The measurement solutions were prepared
from Suprapur nitric acid (Merck GmbH, Germany) and Milli-
Q-water, which were also measured and subtracted as blank.
Rhenium standard solution (10 mg/L, ESI, Elemental Scientific,
Omaha, NE, USA) was added to each measurement solution as
an internal standard, to account for plasma instabilities during
the measurement. Instrument settings, such as gas flows, were
tuned daily.
The measurement was performed in low-resolution mode,
scanning the masses 149–170 and for the internal standard 185
and 187. A standard solution containing stable isotopes of rare
earth elements, including Er, was measured at the start of the
measurement sequence as a performance check.
Chemical Purity
The chemical purity of the sample was determined using ICP-
OES (Agilent ICP-OES 5110). Zn- and Er-containing standard
solutions (0.1, 0.5, 1, 5 ppm, respectively) were prepared in 2%
HNO3 (Merck Suprapur), using Sigma-Aldrich TraceCERT
R©,
1,000 mg/L Er and Zn ICP standards.
Radiochemical Purity
Radiochemical purities of Sample 5 and Sample [6-7 (dissolved
together to obtain higher activity)] were determined by
radiolabeling, using PSMA-617 as a model compound. The
percentage of 169Er-PSMA-617 obtained was determined using
High-Performance Liquid Chromatography (HPLC) with a C-
18 reversed-phase column (XterraTM MS, C18, 5µm, 150 ×
4.6mm; Waters). The mobile phase consisted of MilliQ water
containing 0.1% trifluoracetic acid (A) and acetonitrile (B) with
a gradient of 95% A and 5% B to 20% A and 80% B over a
period of 15min at a flow rate of 1.0 mL/min. A sample of the
radiolabeling mixture was diluted in MilliQ water containing
sodium diethylenetriamine-pentaacetic acid (Na-DTPA; 50µM)
prior to injection into the HPLC instrument.
System evaluation
169Er has a negligible emission of photon radiation. Therefore,
before labeling experiments, the detection of 169Er using a
radio-HPLC detector was assessed by comparison to 177Lu.
Supplementary Figure 4 shows the comparison of the HPLC
chromatograms of ∼0.3 MBq free activity for 169Er and 177Lu,
respectively. Before injecting the samples, the HPLC column was
cleaned by running several blanks using DTPA solution to ensure
the detection of 169Er.
Preparation of radioligands
PSMA-617 (ABX GmbH, Radeberg, Germany) was labeled with
169Er under standard conditions at a molar activity of 10
MBq/nmol. A stock solution of PSMA-617 (1mM) was mixed
with a solution of 169Er in 0.05M HCl and the pH adjusted
to 4.0 with the addition of sodium acetate solution (0.5M, pH
8). The reaction mixture was incubated for 20min at 95◦C.
Quality control of 169Er-PSMA-617 was performed using HPLC,
as reported above.
As a control compound, PSMA-617 was labeled with 177Lu
(carrier-free in 0.04M HCl; ITM, Germany) at a molar activity
of 10 MBq/nmol, according to a previously-published procedure
(49). Quality control of 177Lu-PSMA-617 was also performed
using HPLC.
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In vitro Viability Studies
Cell Culture
Sublines of the androgen-independent PC-3 human prostate
cancer cell line, PSMA-positive, PC-3 PIP tumor cells were kindly
provided by Prof. Martin Pomper (Johns Hopkins University
School of Medicine, Baltimore, MD, USA) (50). The cells were
grown in RPMI cell culturemedium supplemented with 10% fetal
calf serum, L-glutamine and antibiotics, as well as puromycin
(2µg/mL), to maintain PSMA expression (51–53).
A tumor cell viability assay was performed using PC-3
PIP/flu tumor cells treated with 169Er-PSMA-617 and 177Lu-
PSMA-617 (0.01–10 MBq/mL), respectively. The assay was
performed according to a previously-published method using
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (7). PC-3 PIP tumor cells (2,500 cells in 200 µL
RPMI medium with supplements) were seeded in 96-well plates
and incubated overnight (37◦C; 5% CO2) to allow adhesion
of the tumor cells. 169Er-PSMA-617 or 177Lu-PSMA-617 (10
MBq/nmol, the highest achievable molar activity for 169Er-
PSMA-617) were diluted in RPMI medium without supplements
to an activity concentration of 0.1–10 MBq/mL. The tumor cells
were washedwith 200µL phosphate buffered saline (PBS, pH 7.2)
prior to the addition of the radioligand dilutions (200 µL/well).
Control cells were sham-treated with RPMI medium without the
addition of radioligands. After a 4 h incubation period (37◦C; 5%
CO2), tumor cells were washed with 200 µL PBS and fresh PRMI
medium (with supplements) was added to each well. Tumor
cell viability was determined after 6 days of incubation at 37◦C,
5% CO2. MTT reagent (5 mg/mL in PBS, 30 µL per well) was
added to each well, followed by incubation of the well plates for
4 h. The dark-violet formazan crystals were dissolved with 200
µL dimethyl sulfoxide. The absorbance was measured at 560 nm
using amicroplate reader (Victor X3, Perkin Elmer). Cell viability
was quantified by expressing the absorbance of the test samples as
a percentage of the absorbance of untreated tumor cell samples,
which was set to 100%.
RESULTS
Irradiation and Mass Separation
In total, five ampoules containing 168Er2O3 were used for
169Er production at the ILL nuclear reactor, with a theoretical
yield between 25 and 48 GBq. After the irradiations, the
ampoules were transported to the CERN-MEDICIS facility.
Supplementary Figure 5A shows the γ-ray spectrum of
commercially-available carrier-added 169Er (supplied by
b.e. Imaging GmbH) as a representative spectrum for
post-irradiation. The product had a reported radionuclidic
impurity ≤0.38% of the 169Er activity, with 177Lu (0.02%) the
main impurity.
The mass 169 ion beam was implanted into seven solid
catchers (two collections were performed for two ampoules). The
mass separation was combined with resonant laser ionization
to enhance element selectivity for the erbium ionization, as
well as the overall separation efficiency. Thus, 169Er activities
were increased up to a factor of four compared to the surface
ionization technique (37). The presence of trace quantities of
Yb (<400 ppm) in the target material (168Er2O3) led to the co-
production of 169Yb (t1/2 = 32 d) due to the high thermal neutron
capture cross-section of 168Yb (σ: 2400 b) (10). As a result, after
the mass separation process, 169Yb (isobar of 169Er) was observed
as a radionuclidic impurity (Supplementary Figure 5B). The
average collection time was 63 hours, with separation efficiencies
of up to 0.5%. To the best of our knowledge, to date, only a
few measurements were reported for the emission probabilities
of 169Er, with large discrepancies (20%) for the two lines at
109.8 and 118.2 keV (54). Moreover, 169Er has the same γ-ray
peak (109.78 keV, 0.0013%) as 169Yb (109.78 keV, 17.39%) with
much lower intensity (8), which made difficult to perform precise
169Er activity measurements of the samples by means of γ-ray
spectrometry. Therefore, separation efficiencies were determined
based on the theoretical initial and final 169Er activities measured
using LSC (after chemical separation). Since activity loss during
the ampoule opening and transferring were not taken into
consideration, the actual separation efficiencies are expected to
be higher than the reported values.
Radiochemical Separation
The zinc layer, containing the implanted 169Er activity and
the isobar 169Yb, was dissolved from the gold foil. Cation and
extraction chromatographic resins were used for the effective
separation of 169Er from isobars and macro quantities of zinc
to obtain chemically and radionuclidically pure 169Er. DGA
extraction resin was used for the first separation step, which
required the use of concentrated nitric acid as a loading solution
for the separation of macro quantities of Zn from the lanthanides.
ICP-OES results showed that traces of zinc (300 ppb) were
retained on the resin (Supplementary Figure 6) and eluted
together with 169Er and 169Yb using 0.05M HCl. The separation
of lanthanides (Er and Yb) was, subsequently performed using
Sykam cation exchange resin. An example of the separation
profile is presented in Figure 3A. The α-hydroxyisobutyric acid
(α-HIBA), used as a complexing agent to separate lanthanides,
was removed by passing the eluent through LN3 extraction resin.
It was also important to use this resin to eliminate Zn from the
desired product, as well as to concentrate the desired product
in a small volume. This three-step separation process (DGA,
Sykam, and LN3 resin) was initially applied to obtain 169Er with
high radionuclidic and chemical purity. However, quality control
analysis of the final product (section Quality Control) showed
that a three-step separation process was not sufficient to reach the
required high chemical purity. Thus, an additional purification
step, using the TK200 resin, was added to separate the remaining
Zn from the final product (Figure 3B).
Quality Control
Assessment of the quality control steps is crucial for the
development of novel radionuclides toward nuclear medical
applications (55). As part of the quality control processes, activity,
radionuclidic purity, isotope ratio, radiochemical purity and
chemical purity measurements were performed to evaluate the
success of the mass and chemical separation methods (Figure 4).
In total, seven 169Er samples were analyzed using different
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FIGURE 3 | (A) Separation profile of 169Yb and 169Er using Sykam cation exchange resin and α-HIBA as eluent, (B) scheme of the chemical separation process for
the mass-separated 169Er samples.
FIGURE 4 | Quality control analyses applied to the 169Er samples after
chemical separation (LSC, Liquid Scintillation counting, ICP-MS, Inductively
Coupled Plasma Mass Spectrometry; HPLC, High-Performance Liquid
Chromatography; ICP-OES, Inductively Coupled Plasma—Optical Emission
Spectrometry).
techniques (Table 3). Samples 6 and 7 were dissolved together to
obtain higher activity toward an in-vitro experiment.
Activity Standardization
Gamma-ray spectrometry measurements were performed before
and after dissolving the zinc layer from the gold foils to evaluate
the fraction of the 169Er implanted into the zinc layer and the
gold backing, respectively. Except for the first sample, the 169Er
activities that remained on the gold foils were negligible.
TABLE 3 | Quality control analysis and results obtained for the mass-separated
samples post-chemical processing.
S1 S2 S3 S4 S5 S6-7
Activity measurement (MBq) 52.9 23.4 8.59 4.70 73.2 93.4
Radionuclidic purity (%) >99.9 >99.9 >99.9 >99.9 >99.9 >99.9
Isotopic ratio (168/169) 1.66 1.60 14.62 11.94 n.d n.d
Chemical purity n.d n.d n.d n.d 0.49 µg Zn n.d
Radiochemical purity (%) n.d n.d n.d n.d 0* >98%
n.d., not determined.
*The radiolabeling of PSMA-617 was not possible.
In order to perform precise 169Er activity measurements, a
purified 169Er solution was used for the activity standardization
using the TDCR technique and its activity concentration was
measured as 798.5 ± 5.9 kBq/g (0.33%, k = 1). The uncertainty
budget of the measurement is given in Supplementary Table 1.
An efficiency calibration curve was constructed based on the
activity concentration determined by the TDCR technique
and stored in the LSC software to enable routine activity
measurements. Subsequently, activity measurements of all the
purified 169Er samples were performed using calibrated LSC.
Radionuclidic Purity
Figure 5 shows an example of a γ-ray spectrum of 169Er after
chemical separation. Thanks to the effective removal of 169Yb
(Figure 3A), no radionuclidic impurity was determined after 15
days counting time. The background spectrum was taken shortly
after the measurement to check for its interference. The two
169Er γ-ray peaks at 109 and 118 keV were observed (the inset
of Figure 5), as well as the intense peaks at 50 keV and 57–59
keV, which correspond to the X-ray lines of 169Er.
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FIGURE 5 | Representative γ-ray spectrum of 169Er product after chemical
separation (counting time: 15 days, sample detector distance: 15 cm) and
background spectrum (counting time: 2 days). The inset shows a zoom of the
two lines at 109 and 118 keV, respectively.
Isotopic Ratio
After the mass and chemical separation processes, four samples
were analyzed to determine the mass 168 and 169 ratios using
a Sector Field Inductively Coupled Plasma Mass Spectrometer
(SF-ICP-MS). The results showed that the tail of 168Er was
more pronounced in Samples 3 and 4 than Samples 1 and 2
(Table 3). Sample 5 and Sample 6-7 were not analyzed, since
these samples were used for radiolabeling. The analytical method
was validated by measuring the 168Er enriched materials, which
were in good agreement with their certificate of analysis (CoA)
(Supplementary Table 2).
Chemical and Radiochemical Purity
After the three-step separation process, Sample 5 was used
to test the preparation of 169Er-PSMA-617 at a molar activity
of 10 MBq/nmol. The radiolabeling of PSMA-617, failed due
to the presence of 0.49 µg Zn impurity (determined by
ICP-OES) competing with the 169Er for the DOTA chelator
of PSMA-617.
To investigate the quantity of Zn that will affect the labeling
efficiency, labeling experiments were performed with non-
carrier-added 177Lu (as a surrogate for 169Er) and DOTANOC
in the presence of different masses of non-radioactive Zn
(Supplementary Figure 7). These experiments revealed that
radiolabeling of the compound was not possible in the presence
of≥0.2µg Zn. Thus, samples 6 and 7 were dissolved together and
purified, utilizing TK200 resin to separate the remaining Zn.
Preparation of radioligand
Samples 6 and 7 were dissolved, combined, and used to prepare
169Er-PSMA-617 at a molar activity of 10 MBq/nmol with a
radiochemical purity of >98% (Figure 6).
FIGURE 6 | Representative HPLC radiochromatogram of 169Er-PSMA-617
prepared at 10 MBq/nmol, demonstrating the product peak and its retention
time in minutes (tR = 8.6 ± 0.1min) (pH: 4.5, T: 95
◦C, 20min incubation).
FIGURE 7 | Results of PC-3 PIP tumor cell viability study performed with
169Er-PSMA-617 (n = 1, SD refer to intraexperimental variation) and
177Lu-PSMA-617 (n = 3, SD refer to interexperimental variation).
In vitro Viability Studies
The radioligand 169Er-PSMA-617 was tested in a tumor cell
viability assay (in vitro) to investigate its therapeutic potential
in comparison to the clinically-established 177Lu-PSMA-617.
Exposure of PC-3 PIP tumor cells to 169Er-PSMA-617 resulted in
reduced tumor cell viability (89 ± 4% and 69 ± 7%) when 5 and
10 MBq/mL, respectively, were applied. At lower concentrations
of the applied radioligand (0.1–2.5 MBq/mL) the cell viability
was unaffected compared to sham-treated control cells. 177Lu-
PSMA-617 had a greater effect on tumor cell viability, resulting
in 72 ± 1% and 62 ± 3% viable cells after exposure to 5
and 10 MBq/mL, respectively. Also, tumor cell viability was
reduced at lower applied activity concentrations of 1.0 and 2.5
MBq/mL resulting in 80 ± 1% and 79 ± 1% viable tumor
cells, respectively (Figure 7). It is important to note that, due
to the limited availability of 169Er, the experiment could only
be performed once in a setting that does not fully reflect the
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therapeutic potential of this novel radionuclide. The molar
activity of 169Er-PSMA-617 was relatively low (10 MBq/nmol),
and hence, receptor saturation effects were likely to occur. In
order to enable effective cell killing, the radioligand should
be prepared at higher molar activity and applied at higher
activity concentrations.
DISCUSSION
In the previous mass separation experiment at the CERN-
MEDICIS facility, 169Er was thermally ionized (37).
This ionization method, however, was prone to isobaric
contamination from elements with similar or lower
ionization potential (37). Different studies performed on
other radionuclides demonstrated that element-selective laser
resonance ionization can provide significantly higher ionization
efficiency for the element of interest and, thus, reduce the
concentration of isobars in the final product (38, 42). As a result,
the surface ionization technique used at MEDICIS was upgraded
with a resonant ionization laser ion source. Although higher
activities of 169Er were extracted compared to the previous study
(169Er activities were increased up to a factor of four) (37), there
is still room for further improvement of the overall efficiency and
beam purity by developing an ad hoc isotope-selective ionization
process for 169Er. The quantity of 168Er target material is several
orders of magnitude greater than the 169Er produced; the erbium
ionization led to a broad 168Er ion beam after the electromagnet,
which tailed on neighboring masses, namely, at mass 169. As
one can see from Table 3, it resulted in a prevalence of 168Er
over 169Er still after mass separation. A first trial to increase the
169Er isotopic ratio, by narrowing laser linewidth, failed, and the
results worsened (collected samples S3 and S4). Furthermore, the
parallel ionization of bulk amounts of 168Er can reduce the ion
source performance, impeding the proper separator adjustment.
This can be solved with the application of an isotope-selective
laser ionization scheme or optimization of the mass separator for
high-flux ion-beam operation (40).
During the mass separation process, isobaric contaminants
can also be extracted due to surface ionization and non-
resonant laser ionization. They could also be collected in the
Zn-coated gold foils, such as 169Yb, which was observed by
γ-ray spectrometry after the mass separation process. The
presence of 169Yb would affect the dosimetric evaluation of the
169Er radiopharmaceutical. Moreover, the chemical purity of the
final product would have a direct effect on the radiolabeling
of the desired radionuclide to a target molecule (56, 57).
Thus, a radiochemical separation process was necessary for
the separation of 169Er from the isobaric contaminants (169Yb)
and soluble residues of the Zn-coated gold foil to make the
desired radionuclide available in a purified form suitable for
radiolabeling procedures.
As mentioned previously, separation of lanthanides is a
particularly challenging issue, due to their similar chemical
behavior. Previously, Chakravarty et al. used an electrochemical
separation method for the complete removal of 169Er from 169Yb
(58). The method was based on a two-step electro-amalgamation
technique, the selective reduction of Yb3+ to Yb2+ followed by
its preferential amalgamation on to a mercury cathode. To date,
considerable effort has been expended on the testing of various
chelating agents for lanthanide separation (59). It was shown that
α-hydroxy-isobutyric acid (α-HIBA) exhibits a consistent trend
across the entire lanthanide series (60–64). In the present study,
the complete removal of 169Yb from 169Er was accomplished
using Sykam macroporous cation exchange resin and α-HIBA
eluent. Zinc separation was achieved using different extraction
resins (DGA, LN3, and TK200). It is worth mentioning that the
Zn quantity reported in the commercially-available non-carrier-
added 177Lu (ITM, Germany) is ≤0.1 µg/GBq with an activity
concentration of 37.5 GBq/mL (80 µL 3 GBq 177Lu can contain
0.3 µg Zn). This quantity of Zn does not affect labeling due to the
high activity concentration of the 177Lu solution. However, the
activity concentration of the mass-separated 169Er solutions are
much lower than the commercially-available non-carrier-added
177Lu solution. Thus, even ppb levels of Zn impurity could affect
the labeling efficiency (Table 3).
In order to characterize 169Er with regard to its potential
as a therapeutic radionuclide, extensive in vitro and in vivo
studies will be necessary. In this regard, the stability of DOTA
complexes has to be assessed to confirm stable coordination of
169Er using biomolecules that are currently used with 177Lu. This
will, however, only be possible once the radionuclide can bemade
available in larger quantities and at a quality that allows the
preparation of radioligands at high molar activity as it is feasible
with other therapeutic radionuclides, including 177Lu and 161Tb.
A typical clinical dose of 169Er (Eβ−av = 100 keV) is expected
to be several GBq, comparable to that of clinically applied 177Lu
(Eβ−av = 133.6 keV) labeled PSMA-617. As was presented, the
activities obtained were sufficient for a preliminary in vitro assay,
however, still fall well short for extensive pre-clinical studies.
If the overall efficiencies could be improved from 0.5 to 20%
(39, 43–45), it will be possible to reach higher 169Er activities.
Moreover, for the present study, irradiations were performed
for 7 days. For an industrial production, one could irradiate
for longer, minimizing the activity loss during transport and
chemical separation, and increasing the yield of 169Er.
CONCLUSION
In this study, radionuclidically pure 169Er was produced at high
specific activities by means of neutron irradiation, followed
by mass and chemical separation processes, respectively. By
combining surface ionization with resonant laser ionization,
169Er activities were increased up to a factor of four compared
to the previously-published study. Further developments of
the mass separation process, such as the application of an
isotope-selective laser ionization scheme and optimization of the
mass separator for high-flux ion-beam operation, are needed to
increase the overall separation efficiencies and to provide higher
activities of 169Er in future. The availability of the β−-particle-
emitting 169Er is particularly important to perform pre-clinical
studies, in combination with the pure Auger electron emitter
165Er. This combination will help us explore the additional
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therapeutic effect of Auger electrons to β−-particles, as in the
case of 161Tb, which will certainly be of scientific relevance.
Enhanced knowledge of the additive therapeutic effects of Auger
electrons will likely be well-received by the nuclear medicine
community and ought to pave the way toward more efficient
cancer treatment, particularly, for the treatment of single cancer
cells and small metastases.
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